

Leslie Z Benet, Fcp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7026649/publications.pdf>

Version: 2024-02-01

209
papers

21,707
citations

16411

64
h-index

9553

142
g-index

212
all docs

212
docs citations

212
times ranked

13240
citing authors

#	ARTICLE	IF	CITATIONS
1	Can <i>In Vitro</i> – <i>In Vivo</i> Extrapolation Be Successful? Recognizing the Incorrect Clearance Assumptions. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1022-1035.	2.3	16
2	Does Addition of Protein to Hepatocyte or Microsomal <i>In Vitro</i> Incubations Provide a Useful Improvement in <i>In Vitro</i> - <i>In Vivo</i> Extrapolation Predictability?. <i>Drug Metabolism and Disposition</i> , 2022, 50, 401-412.	1.7	3
3	State of the Art and Uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): New Additions, Revisions, and Citation References. <i>AAPS Journal</i> , 2022, 24, 37.	2.2	22
4	Volume of Distribution is Unaffected by Metabolic Drug–Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2021, 60, 205-222.	1.6	11
5	Successful and Unsuccessful Prediction of Human Hepatic Clearance for Lead Optimization. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3546-3559.	2.9	29
6	Investigating Intestinal Transporter Involvement in Rivaroxaban Disposition through Examination of Changes in Absorption. <i>Pharmaceutical Research</i> , 2021, 38, 795-801.	1.7	5
7	Using Individualized Patient Data for Prediction of Population Dosing Recommendations Versus Predictions of Individualized Patient Dosing. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 734-735.	1.0	0
8	There is Only One Valid Definition of Clearance: Critical Examination of Clearance Concepts Reveals the Potential for Errors in Clinical Drug Dosing Decisions. <i>AAPS Journal</i> , 2021, 23, 67.	2.2	19
9	Effects of Single Dose Rifampin on the Pharmacokinetics of Fluvastatin in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 480-485.	2.3	2
10	Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans. <i>Pharmaceutical Research</i> , 2021, 38, 1139-1156.	1.7	5
11	Analyzing Potential Intestinal Transporter Drug-Drug Interactions: Reevaluating Ticagrelor Interaction Studies. <i>Pharmaceutical Research</i> , 2021, 38, 1639-1644.	1.7	3
12	Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis. <i>Pharmacology</i> , 2020, 105, 145-163.	0.9	32
13	The Critical Role of Passive Permeability in Designing Successful Drugs. <i>ChemMedChem</i> , 2020, 15, 1862-1874.	1.6	53
14	Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban Disposition. <i>Pharmaceutical Research</i> , 2020, 37, 208.	1.7	15
15	Investigating the Theoretical Basis for <i>In Vitro</i> – <i>In Vivo</i> Extrapolation (IVIVE) in Predicting Drug Metabolic Clearance and Proposing Future Experimental Pathways. <i>AAPS Journal</i> , 2020, 22, 120.	2.2	21
16	The Necessity of Using Changes in Absorption Time to Implicate Intestinal Transporter Involvement in Oral Drug-Drug Interactions. <i>AAPS Journal</i> , 2020, 22, 111.	2.2	10
17	A Simple Methodology to Differentiate Changes in Bioavailability From Changes in Clearance Following Oral Dosing of Metabolized Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 306-315.	2.3	8
18	Challenging the Relevance of Unbound Tissue-to-Blood Partition Coefficient (K_{pu}) on Prediction of Drug-Drug Interactions. <i>Pharmaceutical Research</i> , 2020, 37, 73.	1.7	6

#	ARTICLE	IF	CITATIONS
19	Predicting Interactions between Rifampin and Antihypertensive Drugs Using the Biopharmaceutics Drug Disposition Classification System. <i>Pharmacotherapy</i> , 2020, 40, 274-290.	1.2	6
20	Are There Any Experimental Perfusion Data that Preferentially Support the Dispersion and Parallel-Tube Models over the Well-Stirred Model of Organ Elimination?. <i>Drug Metabolism and Disposition</i> , 2020, 48, 537-543.	1.7	25
21	How Transporters Have Changed Basic Pharmacokinetic Understanding. <i>AAPS Journal</i> , 2019, 21, 103.	2.2	22
22	Food, Acid Supplementation and Drug Absorption – a Complicated Gastric Mix: a Randomized Control Trial. <i>Pharmaceutical Research</i> , 2019, 36, 155.	1.7	3
23	In Vitro – In Vivo Inaccuracy: The CYP3A4 Anomaly. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1368-1371.	1.7	10
24	Can BDDCS illuminate targets in drug design?. <i>Drug Discovery Today</i> , 2019, 24, 2299-2306.	3.2	7
25	The Presence of a Transporter-Induced Protein Binding Shift: A New Explanation for Protein-Facilitated Uptake and Improvement for In Vitro-In Vivo Extrapolation. <i>Drug Metabolism and Disposition</i> , 2019, 47, 358-363.	1.7	44
26	The Enhancement of Subcutaneous First-Pass Metabolism Causes Nonlinear Pharmacokinetics of TAK-448 after a Single Subcutaneous Administration to Rats. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1004-1012.	1.7	5
27	Interlaboratory Variability in Human Hepatocyte Intrinsic Clearance Values and Trends with Physicochemical Properties. <i>Pharmaceutical Research</i> , 2019, 36, 113.	1.7	16
28	In Vitro-In Vivo Extrapolation and Hepatic Clearance-Dependent Underprediction. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2500-2504.	1.6	42
29	Understanding drug – drug interaction and pharmacogenomic changes in pharmacokinetics for metabolized drugs. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2019, 46, 155-163.	0.8	21
30	Characterization of Fasiglifam-Related Liver Toxicity in Dogs. <i>Drug Metabolism and Disposition</i> , 2019, 47, 525-534.	1.7	7
31	Protein Binding and Hepatic Clearance: Re-Examining the Discrimination between Models of Hepatic Clearance with Diazepam in the Isolated Perfused Rat Liver Preparation. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1397-1402.	1.7	7
32	Ascorbic acid metabolites are involved in intraocular pressure control in the general population. <i>Redox Biology</i> , 2019, 20, 349-353.	3.9	31
33	Evaluating Within-Subject Variability for Narrow Therapeutic Index Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 411-416.	2.3	11
34	Batch-to-Batch and Within-Subject Variability: What Do We Know and How Do These Variabilities Affect Clinical Pharmacology and Bioequivalence?. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 326-328.	2.3	5
35	Predicting Pharmacokinetics/Pharmacodynamics in the Individual Patient: Separating Reality From Hype. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 979-989.	1.0	7
36	Evaluation of the relevance of DILI predictive hypotheses in early drug development: review of in vitro methodologies vs in vivo methodologies. BDDCS classification. <i>Toxicology Research</i> , 2018, 7, 358-370.	0.9	19

#	ARTICLE	IF	CITATIONS
37	Measures of BSEP Inhibition In Vitro Are Not Useful Predictors of DILI. <i>Toxicological Sciences</i> , 2018, 162, 499-508.	1.4	53
38	Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer. <i>Scientific Reports</i> , 2018, 8, 92.	1.6	4
39	Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States. <i>Clinical Infectious Diseases</i> , 2018, 66, 213-219.	2.9	82
40	Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2018, 32, 431-441.	0.7	11
41	Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations. <i>AAPS Journal</i> , 2018, 20, 46.	2.2	46
42	The Universally Unrecognized Assumption in Predicting Drug Clearance and Organ Extraction Ratio. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 521-525.	2.3	32
43	TPT sulfonate, a single, oral dose schistosomicidal prodrug: In vivo efficacy, disposition and metabolic profiling. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2018, 8, 571-586.	1.4	13
44	The Extended Clearance Concept Following Oral and Intravenous Dosing: Theory and Critical Analyses. <i>Pharmaceutical Research</i> , 2018, 35, 242.	1.7	19
45	Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence. <i>EClinicalMedicine</i> , 2018, 2-3, 22-28.	3.2	42
46	An examination of protein binding and protein-facilitated uptake relating to in vitro-in vivo extrapolation. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 123, 502-514.	1.9	63
47	Evaluation of DILI Predictive Hypotheses in Early Drug Development. <i>Chemical Research in Toxicology</i> , 2017, 30, 1017-1029.	1.7	42
48	Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 778-783.	0.5	52
49	Cellular Uptake of Levocetirizine by Organic Anion Transporter 4. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2895-2898.	1.6	12
50	Understanding the Potential Interethnic Difference in Rosuvastatin Pharmacokinetics. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2231-2233.	1.6	3
51	Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2751-2757.	1.6	64
52	Meal Effects Confound Attempts to Counteract Rabeprazole-Induced Hypochlorhydria Decreases in Atazanavir Absorption. <i>Pharmaceutical Research</i> , 2017, 34, 619-628.	1.7	8
53	Insights into solute carriers: physiological functions and implications in disease and pharmacokinetics. <i>MedChemComm</i> , 2016, 7, 1462-1478.	3.5	12
54	Classification of natural products as sources of drugs according to the biopharmaceutics drug disposition classification system (BDDCS). <i>Chinese Journal of Natural Medicines</i> , 2016, 14, 888-897.	0.7	15

#	ARTICLE	IF	CITATIONS
55	BDDCS, the Rule of 5 and drugability. <i>Advanced Drug Delivery Reviews</i> , 2016, 101, 89-98.	6.6	475
56	Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. <i>Lancet HIV</i> , 2016, 3, e521-e528.	2.1	66
57	Hepatic Clearance Predictions from In Vitro-In Vivo Extrapolation and the Biopharmaceutics Drug Disposition Classification System. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1731-1735.	1.7	42
58	Use of the Biopharmaceutics Drug Disposition Classification System (BDDCS) to Help Predict the Occurrence of Idiosyncratic Cutaneous Adverse Drug Reactions Associated with Antiepileptic Drug Usage. <i>AAPS Journal</i> , 2016, 18, 757-766.	2.2	14
59	BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs. <i>AAPS Journal</i> , 2016, 18, 251-260.	2.2	60
60	Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain. <i>Clinical Pharmacokinetics</i> , 2016, 55, 143-167.	1.6	21
61	Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 3229-3235.	1.6	31
62	Response of authors to Ganju and Dias's comments on "Inclusion of Placebos and Blinding for Ascending Dose First-in-Human Studies and Other Underpowered Phase 1 Studies Has Not Been Justified and on Balance is Not Useful" by D. A. Parasrampur and L. Z. B. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 117, 367-367.	1.2	0
63	Inclusion of Placebos and Blinding for Ascending Dose First-in-Human Studies and Other Underpowered Phase 1 Studies has not been Justified and on Balance is Not Useful. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 117, 44-51.	1.2	13
64	pH Dependent but not P-gp Dependent Bidirectional Transport Study of S-propranolol: The Importance of Passive Diffusion. <i>Pharmaceutical Research</i> , 2015, 32, 2516-26.	1.7	21
65	Predicting the Extent of Metabolism Using <i>in Vitro</i> Permeability Rate Measurements and <i>in Silico</i> Permeability Rate Predictions. <i>Molecular Pharmaceutics</i> , 2015, 12, 1456-1466.	2.3	22
66	A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination With Etoposide as Myeloablative Therapy for Autologous Stem Cell Transplantation in Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 377-383.	0.2	2
67	The Use of Betaine HCl to Enhance Dasatinib Absorption in Healthy Volunteers with Rabepazole-Induced Hypochlorhydria. <i>AAPS Journal</i> , 2014, 16, 1358-1365.	2.2	27
68	Mouse liver repopulation with hepatocytes generated from human fibroblasts. <i>Nature</i> , 2014, 508, 93-97.	13.7	232
69	Predicting when Biliary Excretion of Parent Drug is a Major Route of Elimination in Humans. <i>AAPS Journal</i> , 2014, 16, 1085-1096.	2.2	31
70	Distinguishing between the Permeability Relationships with Absorption and Metabolism To Improve BCS and BDDCS Predictions in Early Drug Discovery. <i>Molecular Pharmaceutics</i> , 2014, 11, 1335-1344.	2.3	55
71	Gastric Reacidification with Betaine HCl in Healthy Volunteers with Rabepazole-Induced Hypochlorhydria. <i>Molecular Pharmaceutics</i> , 2013, 10, 4032-4037.	2.3	16
72	Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug-Drug Interaction Potential for Molecular Targeted Agents in Clinical Development. <i>Molecular Pharmaceutics</i> , 2013, 10, 4055-4062.	2.3	143

#	ARTICLE	IF	CITATIONS
73	Effect of P-Glycoprotein on the Rat Intestinal Permeability and Metabolism of the BDDCS Class 1 Drug Verapamil. <i>Molecular Pharmaceutics</i> , 2013, 10, 4038-4045.	2.3	2
74	The Role of BCS (Biopharmaceutics Classification System) and BDDCS (Biopharmaceutics Drug Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70 34-42.	1.6	242
75	Intestinal drug transporters: An overview. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 1340-1356.	6.6	265
76	Drug Discovery and Regulatory Considerations for Improving In Silico and In Vitro Predictions that Use Caco-2 as a Surrogate for Human Intestinal Permeability Measurements. <i>AAPS Journal</i> , 2013, 15, 483-497.	2.2	113
77	Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients. <i>Biopharmaceutics and Drug Disposition</i> , 2013, 34, 442-451.	1.1	29
78	A Step Closer to Personalized Chemotherapy: Consideration of the Influence of Genetic Variation in Hepatic Uptake Transporters on the Metabolism of CYP3A Substrates. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 551-552.	2.3	1
79	Benet L Z and Galeazzi R L: Noncompartmental Determination of the Steady-State Volume of Distribution, <i>J Pharm Sci</i> 68, 1071-1074, 1979- the Backstory. <i>AAPS Journal</i> , 2012, 14, 164-167.	2.2	6
80	BDDCS Class Prediction for New Molecular Entities. <i>Molecular Pharmaceutics</i> , 2012, 9, 570-580.	2.3	78
81	Sotalol Permeability in Cultured-Cell, Rat Intestine, and PAMPA System. <i>Pharmaceutical Research</i> , 2012, 29, 1768-1774.	1.7	18
82	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 95-109.	6.6	65
83	Is Ciprofloxacin a Substrate of P-glycoprotein?. <i>Archives of Drug Information</i> , 2011, 4, 1-9.	1.6	29
84	BDDCS Applied to Over 900 Drugs. <i>AAPS Journal</i> , 2011, 13, 519-547.	2.2	532
85	Intermittent drug dosing intervals guided by the operational multiple dosing half lives for predictable plasma accumulation and fluctuation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2011, 38, 369-383.	0.8	13
86	The BCS, BDDCS, and Regulatory Guidances. <i>Pharmaceutical Research</i> , 2011, 28, 1774-1778.	1.7	77
87	Effects of Uremic Toxins on Transport and Metabolism of Different Biopharmaceutics Drug Disposition Classification System Xenobiotics. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 3831-3842.	1.6	39
88	Clearance (the Rowland) concepts: a downdate and an update. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2010, 37, 529-539.	0.8	27
89	Predicting Drug Disposition via Application of a Biopharmaceutics Drug Disposition Classification System. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010, 106, 162-167.	1.2	98
90	Effect of Single-Dose Rifampin on the Pharmacokinetics of Warfarin in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 540-547.	2.3	27

#	ARTICLE	IF	CITATIONS
91	The FDA Should Eliminate the Ambiguities in the Current BCS Biowaiver Guidance and Make Public the Drugs for Which BCS Biowaivers Have Been Granted. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 405-407.	2.3	35
92	Membrane transporters in drug development. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 215-236.	21.5	2,886
93	Transporter-Based Drug-Drug Interactions and Their Effect on Distribution Volumes. , 2010, , 437-471.		1
94	Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 4413-4419.	1.6	58
95	The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs. <i>Pharmaceutical Research</i> , 2009, 26, 2039-2054.	1.7	375
96	Elucidating Rifampin's Inducing and Inhibiting Effects on Glyburide Pharmacokinetics and Blood Glucose in Healthy Volunteers: Unmasking the Differential Effects of Enzyme Induction and Transporter Inhibition for a Drug and Its Primary Metabolite. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 78-85.	2.3	119
97	A Holy Grail of Clinical Pharmacology: Prediction of Drug Pharmacokinetics and Pharmacodynamics in the Individual Patient. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 133-134.	2.3	18
98	Effects of Drug Transporters on Volume of Distribution. <i>AAPS Journal</i> , 2009, 11, 250-261.	2.2	116
99	The Drug Transporter-Metabolism Alliance: Uncovering and Defining the Interplay. <i>Molecular Pharmaceutics</i> , 2009, 6, 1631-1643.	2.3	176
100	The Use of BDDCS in Classifying the Permeability of Marketed Drugs. <i>Pharmaceutical Research</i> , 2008, 25, 483-488.	1.7	124
101	The Operational Multiple Dosing Half-life: A Key to Defining Drug Accumulation in Patients and to Designing Extended Release Dosage Forms. <i>Pharmaceutical Research</i> , 2008, 25, 2869-2877.	1.7	85
102	Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. <i>Advanced Drug Delivery Reviews</i> , 2008, 60, 717-733.	6.6	379
103	Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 194-204.	2.3	297
104	Review and Critique of the Institute of Medicine Report "The Future of Drug Safety". <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 158-161.	2.3	2
105	Effects of Uptake and Efflux Transporter Inhibition on Erythromycin Breath Test Results. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 828-832.	2.3	48
106	Multiple Transporters Affect the Disposition of Atorvastatin and Its Two Active Hydroxy Metabolites: Application of in Vitro and ex Situ Systems. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 316, 762-771.	1.3	136
107	Effects of renal failure on drug transport and metabolism. , 2006, 109, 1-11.		248
108	Elucidating the Effect of Final-Day Dosing of Rifampin in Induction Studies on Hepatic Drug Disposition and Metabolism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 864-870.	1.3	37

#	ARTICLE	IF	CITATIONS
109	PHARMACOKINETICS OF ATORVASTATIN AND ITS HYDROXY METABOLITES IN RATS AND THE EFFECTS OF CONCOMITANT RIFAMPICIN SINGLE DOSES: RELEVANCE OF FIRST-PASS EFFECT FROM HEPATIC UPTAKE TRANSPORTERS, AND INTESTINAL AND HEPATIC METABOLISM. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1175-1181.	1.7	101
110	IN VITRO AND IN VIVO CORRELATION OF HEPATIC TRANSPORTER EFFECTS ON ERYTHROMYCIN METABOLISM: CHARACTERIZING THE IMPORTANCE OF TRANSPORTER-ENZYME INTERPLAY. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1336-1344.	1.7	78
111	Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System. <i>Pharmaceutical Research</i> , 2005, 22, 11-23.	1.7	1,222
112	There Are No Useful CYP3A Probes that Quantitatively Predict the In Vivo Kinetics of Other CYP3A Substrates and No Expectation that One Will Be Found. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2005, 5, 79-83.	3.4	36
113	HEPATIC MICROSOME STUDIES ARE INSUFFICIENT TO CHARACTERIZE IN VIVO HEPATIC METABOLIC CLEARANCE AND METABOLIC DRUG-DRUG INTERACTIONS: STUDIES OF DIGOXIN METABOLISM IN PRIMARY RAT HEPATOCYTES VERSUS MICROSOMES. <i>Drug Metabolism and Disposition</i> , 2004, 32, 1311-1316.	1.7	91
114	EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCIN. <i>Drug Metabolism and Disposition</i> , 2004, 32, 1239-1246.	1.7	117
115	P-glycoprotein (P-gp/MDR1)-Mediated Efflux of Sex-Steroid Hormones and Modulation of P-gp Expression In Vitro. <i>Pharmaceutical Research</i> , 2004, 21, 1284-1293.	1.7	129
116	Ex Situ Inhibition of Hepatic Uptake and Efflux Significantly Changes Metabolism: Hepatic Enzyme-Transporter Interplay. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 308, 1040-1045.	1.3	104
117	CYP3A4-Transfected Caco-2 Cells as a Tool for Understanding Biochemical Absorption Barriers: Studies with Sirolimus and Midazolam. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 308, 143-155.	1.3	96
118	DISPOSITION OF TACROLIMUS IN ISOLATED PERFUSED RAT LIVER: INFLUENCE OF TROLEANDOMYCIN, CYCLOSPORINE, AND GG918. <i>Drug Metabolism and Disposition</i> , 2003, 31, 1292-1295.	1.7	69
119	In Vivo Modulation of Intestinal CYP3A Metabolism by P-Glycoprotein: Studies Using the Rat Single-Pass Intestinal Perfusion Model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305, 306-314.	1.3	151
120	Unmasking the Dynamic Interplay between Intestinal P-Glycoprotein and CYP3A4. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 300, 1036-1045.	1.3	287
121	Changes in plasma protein binding have little clinical relevance. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 115-121.	2.3	680
122	The Gut as a Barrier to Drug Absorption. <i>Clinical Pharmacokinetics</i> , 2001, 40, 159-168.	1.6	468
123	Red wine decreases cyclosporine bioavailability. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 468-474.	2.3	39
124	Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP1, and MRP2) in CYP3A4-transfected Caco-2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. <i>Pharmaceutical Research</i> , 2001, 18, 1102-1109.	1.7	80
125	A human lymphocyte based ex vivo assay to study the effect of drugs on P-glycoprotein (P-gp) function. <i>Pharmaceutical Research</i> , 2001, 18, 39-44.	1.7	28
126	The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 24-31.	2.3	187

#	ARTICLE	IF	CITATIONS
127	Active secretion and enterocytic drug metabolism barriers to drug absorption IPII of original article: S0169-409X(96)003304. The article was originally published in Advanced Drug Delivery Reviews 20 (1996) 99-112.1. Advanced Drug Delivery Reviews, 2001, 46, 89-102.	6.6	257
128	Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and Caco-2 cell monolayers. British Journal of Pharmacology, 2000, 129, 1235-1243.	2.7	92
129	Chiral Bioequivalence. Clinical Pharmacokinetics, 2000, 39, 459-469.	1.6	16
130	Net secretion of furosemide is subject to indomethacin inhibition, as observed in Caco-2 monolayers and excised rat jejunum. Pharmaceutical Research, 1999, 16, 221-224.	1.7	24
131	Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharmaceutical Research, 1999, 16, 478-485.	1.7	173
132	Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. Journal of Controlled Release, 1999, 62, 25-31.	4.8	279
133	Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers. , 1998, 15, 1520-1524.		38
134	Effects of Ketoconazole on Digoxin Absorption and Disposition in Rat. Pharmacology, 1998, 56, 308-313.	0.9	68
135	Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine*. Clinical Pharmacology and Therapeutics, 1997, 62, 248-260.	2.3	654
136	Tacrolimus oral bioavailability doubles with coadministration of ketoconazole*. Clinical Pharmacology and Therapeutics, 1997, 62, 41-49.	2.3	254
137	Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. Journal of Controlled Release, 1996, 39, 139-143.	4.8	166
138	Active secretion and enterocytic drug metabolism barriers to drug absorption. Advanced Drug Delivery Reviews, 1996, 20, 99-112.	6.6	149
139	The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers*. Clinical Pharmacology and Therapeutics, 1996, 59, 297-303.	2.3	119
140	Morality Play. Science, 1996, 273, 1782-1782.	6.0	0
141	Immunopharmacodynamic Studies of Cyclosporine in Patients Awaiting Renal Transplantation. Journal of Clinical Pharmacology, 1995, 35, 967-973.	1.0	5
142	Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Molecular Carcinogenesis, 1995, 13, 129-134.	1.3	780
143	Time course of cyclosporine and its metabolites in blood, liver and spleen of naive lewis rats: Comparison with preliminary data obtained in transplanted animals. Biopharmaceutics and Drug Disposition, 1995, 16, 303-312.	1.1	4
144	The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine*. Clinical Pharmacology and Therapeutics, 1995, 58, 15-19.	2.3	263

#	ARTICLE	IF	CITATIONS
145	Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 492-497.	2.3	340
146	Hypersensitivity to nonsteroidal anti-inflammatory drugs. <i>Nature Medicine</i> , 1995, 1, 2-4.	15.2	54
147	Determination of aliphatic thiols by fluorometric high-performance liquid chromatography after precolumn derivatization with 2-(4-N-maleimidophenyl)-6-methylbenzothiazole. <i>Pharmaceutical Research</i> , 1995, 12, 155-160.	1.7	3
148	Gender Effects in Pharmacokinetics and Pharmacodynamics. <i>Drugs</i> , 1995, 50, 222-239.	4.9	438
149	Pharmacokinetics of nitroglycerin and its four metabolites during nitroglycerin transdermal administration. <i>Biopharmaceutics and Drug Disposition</i> , 1994, 15, 179-183.	1.1	6
150	HPLC assay for FK 506 and two metabolites in isolated rat hepatocytes and rat liver microsomes. <i>Pharmaceutical Research</i> , 1994, 11, 844-847.	1.7	13
151	Pharmacokinetics of Orally and Intravenously Administered Cyclosporine in Pre- and Post-Kidney Transplant Patients. <i>Journal of Clinical Pharmacology</i> , 1994, 34, 60-67.	1.0	22
152	In vitro and in vivo irreversible plasma protein binding of beclobric acid enantiomers. <i>Chirality</i> , 1993, 5, 120-125.	1.3	13
153	Interpretation and utilization of effect and concentration data collected in an in vivo pharmacokinetic and in vitro pharmacodynamic study. <i>Pharmaceutical Research</i> , 1993, 10, 889-894.	1.7	5
154	Acyl Glucuronides Revisited: Is the Glucuronidation Process a Toxication as Well as a Detoxification Mechanism?. <i>Drug Metabolism Reviews</i> , 1992, 24, 5-47.	1.5	393
155	Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 52, 453-457.	2.3	327
156	Comparison of vasodilatory responses to nitroglycerin and its dinitrate metabolites in human veins. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 52, 590-596.	2.3	17
157	Glutathione S-transferase-mediated metabolism of glyceryl trinitrate in subcellular fractions of bovine coronary arteries. <i>Pharmaceutical Research</i> , 1992, 09, 1460-1464.	1.7	29
158	Nitroglycerin absorption from transdermal systems: formulation effects and metabolite concentrations. <i>Pharmaceutical Research</i> , 1991, 08, 744-749.	1.7	21
159	Drug metabolism and laboratory anesthetic protocols in the rat: examination of antipyrine pharmacokinetics. <i>Pharmaceutical Research</i> , 1991, 08, 544-546.	1.7	24
160	Variable glyceryl dinitrate formation following infusions of glyceryl trinitrate at different vascular sites in the rat. <i>Pharmaceutical Research</i> , 1991, 08, 877-882.	1.7	2
161	Percutaneous penetration kinetics of nitroglycerin and its dinitrate metabolites across hairless mouse skin in vitro. <i>Pharmaceutical Research</i> , 1991, 08, 1231-1237.	1.7	8
162	Pharmacokinetic studies of the nitroglycerin metabolites, 1,2- and 1,3- glyceryl dinitrates, in the rat. <i>Biopharmaceutics and Drug Disposition</i> , 1991, 12, 215-222.	1.1	5

#	ARTICLE	IF	CITATIONS
163	Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. <i>Biopharmaceutics and Drug Disposition</i> , 1991, 12, 467-477.	1.1	3
164	Pharmacokinetics of nitroglycerin and its dinitrate metabolites over a thirtyfold range of oral doses. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 47, 592-598.	2.3	26
165	Irreversible binding of tolmetin glucuronic acid esters to albumin in vitro. <i>Pharmaceutical Research</i> , 1990, 07, 21-27.	1.7	35
166	High-fat meals increase the clearance of cyclosporine. <i>Pharmaceutical Research</i> , 1990, 07, 46-48.	1.7	66
167	In Vitro and in Vivo Testing and Correlation for Oral Controlled/Modified-Release Dosage Forms. <i>Pharmaceutical Research</i> , 1990, 07, 975-982.	1.7	72
168	Effect of Food on the Pharmacokinetics of Cyclosporine in Healthy Subjects Following Oral and Intravenous Administration. <i>Journal of Clinical Pharmacology</i> , 1990, 30, 643-653.	1.0	115
169	HPLC Measurement of Cyclosporine in Blood Plasma and Urine and Simultaneous Measurement of its Four Metabolites in Blood. , 1989, 12, 1451-1462.		9
170	An integrated approach to pharmacokinetic analysis for linear mammillary systems in which input and exit may occur in/from any compartment. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1989, 17, 673-686.	0.6	12
171	Absorption kinetics of cyclosporine in healthy volunteers. <i>Biopharmaceutics and Drug Disposition</i> , 1989, 10, 591-596.	1.1	19
172	Pharmacokinetics of nicotinic acid & salicylic acid interaction. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 46, 642-647.	2.3	25
173	Probenecid-induced changes in the clearance of carprofen enantiomers: A preliminary study. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 45, 500-505.	2.3	40
174	Prediction of the distribution volumes of cefazolin and tobramycin in obese children based on physiological pharmacokinetic concepts. <i>Pharmaceutical Research</i> , 1989, 06, 486-491.	1.7	33
175	Disposition and irreversible plasma protein binding of tolmetin in humans. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 44, 107-114.	2.3	71
176	Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 43, 673-680.	2.3	36
177	General treatment of mean residence time, clearance, and volume parameters in linear mammillary models with elimination from any compartment. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1988, 16, 475-492.	0.6	55
178	Ion-Paired Liquid Chromatographic Method for the Analysis of Pyridostigmine in Plasma. <i>Journal of Liquid Chromatography and Related Technologies</i> , 1987, 10, 2231-2246.	0.9	10
179	Transdermal bioavailability and first-pass skin metabolism: A preliminary evaluation with nitroglycerin. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1987, 15, 423-437.	0.6	36
180	Variable glyceryl dinitrate formation as a function of route of nitroglycerin administration. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 42, 273-277.	2.3	33

#	ARTICLE	IF	CITATIONS
181	Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives. <i>Clinical Pharmacology and Therapeutics</i> , 1986, 39, 425-429.	2.3	28
182	Effect of probenecid on the formation and elimination of acyl glucuronides: Studies with zomepirac. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 38, 121-127.	2.3	67
183	Premarketing observational studies of population pharmacokinetics of new drugs. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 38, 481-487.	2.3	96
184	Peptides and proteins as drugs. <i>Pharmaceutical Research</i> , 1985, 02, 151-156.	1.7	14
185	Pharmacokinetics and metabolism of bepridil. <i>American Journal of Cardiology</i> , 1985, 55, C8-C13.	0.7	67
186	Hydrochlorothiazide Pharmacokinetics and Pharmacologic Effect: The Influence of Indomethacin. <i>Journal of Clinical Pharmacology</i> , 1982, 22, 32-41.	1.0	32
187	Membrane Populations of Bovine Choroid Plexus: Separation by Density Gradient Centrifugation in Modified Colloidal Silica. <i>Journal of Neurochemistry</i> , 1982, 37, 768-774.	2.1	6
188	Effects of Indomethacin and Carprofen on Renal Homeostasis in Rheumatoid Arthritis Patients and in Healthy Individuals. <i>Journal of Clinical Pharmacology</i> , 1981, 21, 493-500.	1.0	10
189	Furosemide kinetics and dynamics after kidney transplant. <i>Clinical Pharmacology and Therapeutics</i> , 1981, 30, 105-113.	2.3	28
190	A standard approach to compiling clinical pharmacokinetic data. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1981, 9, 59-127.	0.6	30
191	Saturable kinetics of intravenous chlorothiazide in the rhesus monkey. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1981, 9, 461-476.	0.6	8
192	High Pressure Liquid Chromatographic Determination of Mecillinam in Human Plasma and Urine. <i>Analytical Letters</i> , 1981, 14, 1433-1447.	1.0	6
193	Renal excretion of pseudoephedrine. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 28, 690-694.	2.3	37
194	Noncompartmental Determination of the Steady-State Volume of Distribution. <i>Journal of Pharmaceutical Sciences</i> , 1979, 68, 1071-1074.	1.6	724
195	Attenuation of furosemide's diuretic effect by indomethacin: Pharmacokinetic evaluation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1979, 7, 265-274.	0.6	38
196	Cefamandole kinetics in uremic patients undergoing hemodialysis. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 26, 592-599.	2.3	17
197	Effect of route of administration and distribution on drug action. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1978, 6, 559-585.	0.6	68
198	Pharmacokinetics of cefamandole using a HPLC assay. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1978, 6, 153-164.	0.6	42

#	ARTICLE	IF	CITATIONS
199	Acute Massive Chloral Hydrate Intoxication Treated with Hemodialysis: A Clinical Pharmacokinetic Analysis. <i>Journal of Clinical Pharmacology</i> , 1978, 18, 136-142.	1.0	30
200	Kinetics of oral ethambutol in the normal subject. <i>Clinical Pharmacology and Therapeutics</i> , 1977, 22, 615-621.	2.3	64
201	The renal elimination of procainamide. <i>Clinical Pharmacology and Therapeutics</i> , 1976, 19, 55-62.	2.3	50
202	Relationship between the pharmacokinetics and pharmacodynamics of procainamide. <i>Clinical Pharmacology and Therapeutics</i> , 1976, 20, 278-289.	2.3	148
203	An integrated approach to the pharmacokinetic analysis of drug absorption. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1974, 2, 525-544.	0.6	27
204	Use of the unanesthetized rhesus monkey as a model for studying the gastrointestinal absorption of drugs. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1974, 2, 417-431.	0.6	9
205	Clearance concepts in pharmacokinetics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1973, 1, 123-136.	0.6	674
206	Addendum 1. Use of isotopes in bioavailability testing. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1973, 1, 83-87.	0.6	8
207	General Treatment of Linear Mammillary Models with Elimination from any Compartment as Used in Pharmacokinetics. <i>Journal of Pharmaceutical Sciences</i> , 1972, 61, 536-541.	1.6	182
208	Use of General Partial Fraction Theorem for Obtaining Inverse Laplace Transforms in Pharmacokinetic Analysis. <i>Journal of Pharmaceutical Sciences</i> , 1971, 60, 1593-1594.	1.6	30
209	Volume Terms in Pharmacokinetics. <i>Journal of Pharmaceutical Sciences</i> , 1969, 58, 639-641.	1.6	43